Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Sam Nizam who wrote (122239)	11/7/2003 10:28:58 AM
From: Taki	Respond to of 150070

HTDS,Announces the Arrivaof Tubercin in the United States Hard to Treat Diseases Incorporated - HTDS - Announces the Arrival of Tubercin i the United States Health/Medical Writers / Business Editors DELRAY BEACH, Fla.--(BUSINESS WIRE)--HTDS-- Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) announces today that it has now been documented that Tubercin(R) arrived in the United States during September 2003. The writing of the protocol for FDA testing took longer than expected which delayed Tubercin's arrival. A contract has been signed and entered into for the formal testing of Tubercin. This is the first step in the FDA process. "I want the shareholders to realize that this is a great leap forward for the company. We will now build momentum and keep HTTD on track," stated Colm King, the newly appointed President. As mentioned in a prior press release, the holistic and homeopathic market size for 2001 was $17.7 billion, according to the National Nutritional Food Association (NNFA). HTTD is initially going for (.1%) one tenth of one percent of the market, which represents $17.7 million in sales. The company is proud of its product Tubercin(R), and is back on target toward achieving its goals and acting on behalf of and in the interest of its shareholders. The expectation of HTTD is that scientific results recorded by a third party other than those associated with HTTD will further our communication efforts in establishing Tubercin(R) as an immunostimulant for combating cancer. Due to a nondisclosure agreement, HTTD is not at liberty to disclose more specifics than the information mentioned above. As the project develops HTTD will keep you posted. Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract summary of the patent..."A carbohydrate complex, which is a mixture of low molecular-weight polysaccaharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL PRODUCT SOURCE: Hard to Treat Diseases Incorporated CONTACT INFORMATION: Hard to Treat Diseases Incorporated, Delray Beach Colm King, 561/272-6900 * end of story *